STOCKHOLM, Sweden--(BUSINESS WIRE)--Medivir AB and Presidio Pharmaceuticals Inc announced today the signing of license agreements for alovudine (MIV-310), Medivir’s phase II compound with potent activity against multidrug resistant HIV, and MIV-410 a preclinical compound which has a novel mechanism of action against HIV and is also efficacious against cytomegalovirus (CMV).
